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BACKGROUND
Robust data on patient-reported outcome measures comparing treatments for clinically 
localized prostate cancer are lacking. We investigated the effects of active monitoring, 
radical prostatectomy, and radical radiotherapy with hormones on patient-reported outcomes.
METHODS
We compared patient-reported outcomes among 1643 men in the Prostate Testing for 
Cancer and Treatment (ProtecT) trial who completed questionnaires before diagnosis, 
at 6 and 12 months after randomization, and annually thereafter. Patients completed 
validated measures that assessed urinary, bowel, and sexual function and specific ef-
fects on quality of life, anxiety and depression, and general health. Cancer-related qual-
ity of life was assessed at 5 years. Complete 6-year data were analyzed according to the 
intention-to-treat principle.
RESULTS
The rate of questionnaire completion during follow-up was higher than 85% for most 
measures. Of the three treatments, prostatectomy had the greatest negative effect on 
sexual function and urinary continence, and although there was some recovery, these 
outcomes remained worse in the prostatectomy group than in the other groups 
throughout the trial. The negative effect of radiotherapy on sexual function was greatest 
at 6 months, but sexual function then recovered somewhat and was stable thereafter; 
radiotherapy had little effect on urinary continence. Sexual and urinary function de-
clined gradually in the active-monitoring group. Bowel function was worse in the radio-
therapy group at 6 months than in the other groups but then recovered somewhat, 
except for the increasing frequency of bloody stools; bowel function was unchanged 
in the other groups. Urinary voiding and nocturia were worse in the radiotherapy 
group at 6 months but then mostly recovered and were similar to the other groups 
after 12 months. Effects on quality of life mirrored the reported changes in function. 
No significant differences were observed among the groups in measures of anxiety, 
depression, or general health-related or cancer-related quality of life.
CONCLUSIONS
In this analysis of patient-reported outcomes after treatment for localized prostate cancer, 
patterns of severity, recovery, and decline in urinary, bowel, and sexual function and as-
sociated quality of life differed among the three groups. (Funded by the U.K. National 
Institute for Health Research Health Technology Assessment Program; ProtecT Current 
Controlled Trials number, ISRCTN20141297; ClinicalTrials.gov number, NCT02044172.)
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A s reported in a companion article in the Journal, the U.K. National Institute for Health Research–supported Prostate 
Testing for Cancer and Treatment (ProtecT) trial 
has shown no significant difference in prostate-
cancer–specific mortality or all-cause mortality 
among men with prostate cancer detected by 
prostate-specific antigen (PSA) testing who were 
randomly assigned to radical prostatectomy, ac-
tive monitoring (a surveillance strategy), or radi-
cal conformal radiotherapy with neoadjuvant 
hormonal therapy, at a median of 10 years of 
follow-up; however, the ProtecT trial has shown 
higher rates of metastases and disease progres-
sion among men in the active-monitoring group 
than among men in the radical-treatment groups.1 
In this article, we focus on the prospective as-
sessments by the participants of the effects of 
treatments on urinary, sexual, and bowel func-
tion and specific and general aspects of quality 
of life; validated measures were completed reg-
ularly by the participants to assess these out-
comes.
Systematic reviews2-5 and studies involving 
large, prospective cohorts6,7 have shown particu-
lar effects on urinary, bowel, and sexual func-
tion and little effect on general quality of life 
after radical treatments, but clear comparisons 
among contemporary treatments have been hin-
dered by differences in outcome definitions, 
limited use of validated outcome measures, 
mostly short-term follow-up, and sparse data on 
radiotherapy or active surveillance programs.8 
Randomized clinical trials have not included 
the full range of validated patient-reported out-
come measures. Using a questionnaire specific to 
the study, the investigators in the Scandinavian 
Prostate Cancer Group-4 (SPCG-4) trial showed 
that prostatectomy had a greater effect on sexual 
and urinary function and quality of life than did 
watchful waiting among men who had clinically 
identified prostate cancer.9,10 Using three single 
symptoms items, the investigators in the Pros-
tate Cancer Intervention versus Observation Trial 
(PIVOT) reported worse urinary incontinence 
and erectile dysfunction after prostatectomy than 
after observation, and similar bowel function, 
among men with PSA-detected prostate cancer.11 
Here we present a comprehensive set of patient-
reported outcomes from the ProtecT trial over 
6 years of follow-up.
Me thods
ProtecT Trial Participants
Details of the recruitment methods of the ProtecT 
trial and the baseline data have been published 
previously (see also Table S1A in the Supplemen-
tary Appendix, available with the full text of this 
article at NEJM.org).12 In brief, after population-
based PSA testing and standardized diagnostic 
procedures had been performed between 1999 
and 2009, a total of 2896 men received a diag-
nosis of prostate cancer, including 2664 men 
with clinically localized disease. A total of 1643 
of these men (62%) underwent randomization; 
545 were assigned to active monitoring (regular 
PSA testing with clinical review to enable change 
to radical treatment if disease progressed), 553 to 
radical prostatectomy (most of the operations in-
volved an open retropubic, nerve-sparing ap-
proach), and 545 to radiotherapy (external-beam 
three-dimensional conformal radiotherapy deliv-
ered at a total dose of 74 Gy in 37 fractions, 
along with neoadjuvant androgen deprivation 
therapy). The prespecified primary outcome was 
prostate-cancer mortality at a median of 10 years 
of follow-up, with prostate-cancer–related deaths 
defined as deaths that were definitely or proba-
bly due to prostate cancer or its treatment.13
Trial Design and Oversight
The authors vouch for the accuracy and com-
pleteness of the data and analyses and for the 
fidelity of the study to the protocol, available at 
NEJM.org. The ProtecT trial was approved by the 
East Midlands (formerly Trent) Multicenter Re-
search Ethics Committee in the United Kingdom 
(reference number 01/4/025). The ProtecT trial 
followed the Consolidated Standards of Report-
ing of Trials (CONSORT) guidelines for patient-
reported outcomes.14
Patient-Reported Outcome Measures
Patient-reported outcomes were prespecified sec-
ondary outcomes that were assessed with the 
use of validated measures in four key domains15 
(Table 1). Domain A comprised urinary function, 
including urinary incontinence and lower uri-
nary tract symptoms, and the effect of urinary 
function on quality of life; outcomes were as-
sessed with the use of the International Consul-
tation on Incontinence Questionnaire (ICIQ),16 
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the Expanded Prostate Cancer Index Composite 
(EPIC) instrument,17 and the International Con-
tinence Society Male Short-Form (ICSmaleSF) 
questionnaire.18 Domain B comprised sexual 
function, including erectile function, and the 
effect of sexual function on quality of life; out-
comes were assessed with the use of the EPIC 
instrument.17 Domain C comprised bowel func-
tion, including the occurrence of loose and bloody 
stools and incontinence, and the effect of bowel 
function on quality of life; outcomes were as-
sessed with the use of the EPIC instrument.17 
Domain D comprised measures of health-related 
quality of life, which included general health 
status (as assessed with the use of the Medical 
Outcomes Study 12-Item Short-Form General 
Health Survey [SF-12]19), anxiety and depression 
(as assessed with the use of the Hospital Anxiety 
and Depression Scale [HADS]),20 and cancer-
related quality of life (as assessed with the use 
of the European Organization for Research and 
Treatment of Cancer Quality-of-Life Question-
naire–Core 30 module (EORTC QLQ-C30).21
Study questionnaires were completed at base-
line (i.e., at the time of biopsy, before the diag-
nosis was known), at 6 and 12 months after 
randomization, and annually thereafter. The 
ICSmaleSF questionnaire, the SF-12, and the HADS 
were included in the study during the entire 
course of the ProtecT trial; the ICIQ was included 
starting in 2001, and the EPIC instrument was 
included starting in 2005. Because the EORTC 
QLQ-C30 concerns cancer-related quality of life, 
this questionnaire was included at year 5 only. 
Patient-reported outcome measures were scored 
and analyzed as recommended by the authors 
of the assessments, with key items identified to 
aid in the interpretation of clinical relevance 
(Table 1). Men received therapies as required 
for side effects of treatments in accordance 
with guidelines,22-25 and their questionnaire re-
sponses include influences of the effects of these 
therapies.
Statistical Analysis
Analyses were performed according to the inten-
tion-to-treat principle, and summary statistics 
and 95% confidence intervals are reported ac-
cording to randomization group. For each out-
come measure in turn, all available data after 
randomization for each man were compared 
between the treatment groups; a likelihood-ratio 
test evaluated the evidence against a null hypoth-
esis of equal mean response over 6 years of 
follow-up across the three groups. Two-level 
random-effects models were used to accommo-
date the correlation between the repeated assess-
ments for each man. Two-level linear models 
Domain A: Urinary function and effect on quality of life
Incontinence
Assessment score: ICIQ16 score
Key item: EPIC17 pad-use item
Effect on quality of life: ICIQ interference with quality of life item
Lower urinary tract symptoms
Assessment scores: ICSmaleSF18 voiding score, EPIC urinary summary 
score
Key item: ICSmaleSF nocturia
Effect on quality of life: ICSmaleSF effect of urinary symptoms on quality  
of life item
Domain B: Sexual function and effect on quality of life
Erectile dysfunction
Key item: EPIC item on erections firm enough for intercourse
Effect on quality of life: EPIC problem with erectile dysfunction item
Overall sexual function
Assessment scores: EPIC sexual function subscale score, EPIC sexual 
bother subscale score
Effect on quality of life: EPIC impact of sexual dysfunction item
Domain C: Bowel function and effect on quality of life
Assessment scores: EPIC bowel function subscale score, EPIC bowel 
 bother subscale score
Key items: EPIC items on loose stools, fecal incontinence, bloody stools
Effect on quality of life: EPIC impact of bowel habits item
Domain D: Health-related quality of life
General health status: SF-12 physical health and mental health19
HADS percentage of potentially significant clinical cases of anxiety and 
 depression20
Cancer-related quality of life: EORTC QLQ-C3021
*  Table S2 in the Supplementary Appendix provides patient-reported outcomes 
for EPIC (Expanded Prostate Cancer Index Composite) urinary incontinence 
subscale score, urinary bother subscale score, urinary obstruction/irritation 
subscale score, sexual summary score, and bowel summary score; ICSmaleSF 
(International Continence Society Male Short-Form) questionnaire urinary in-
continence score and daytime urine frequency score; HADS (Hospital Anxiety 
and Depression Scale) mean anxiety subscale and depression subscale score; 
and EORTC QLQ-C30 (European Organization for Research and Treatment  
of Cancer Quality-of-Life Questionnaire–Core 30 module) global health status 
score, five functional scales, and nine symptom scales. ICIQ denotes Interna-
tional Consultation on Incontinence Questionnaire, and SF-12 Medical Out-
comes Study 12-Item Short-Form General Health Survey.
Table 1. Patient-Reported Outcome Measure Domains, Scores, and Items.*
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(also known as variance component models) were 
used for continuous measures, and two-level 
logistic models were used for binary measures; 
normal random-effects distributions were used 
in both the linear and logistic models. All mod-
els included as covariates the variables that were 
used for stratification or minimization in the 
randomization process: age and PSA level at base-
line (continuous variables) and Gleason score 
and study center (dummy variables). Although 
we had planned to include baseline measures as 
covariates, we did not include them because the 
EPIC instrument and the ICIQ were not available 
for men who were recruited early in the trial. No 
meaningful differences in patient-reported out-
come measures across treatment groups were 
observed at baseline.15
Missing data were not imputed; all data from 
men with at least one measure available after 
randomization were included in the analysis. 
The random-effects models used here provided 
unbiased estimates of treatment comparisons, 
under the assumption that any systematic deter-
minant of data being missing was predictable 
from the covariates that were included in the 
model, such as the treatment group or earlier 
measures of the outcome (i.e., data were missing 
at random).26 All analyses were performed with 
the use of Stata software, version 14.1 (StataCorp).
R esult s
Response Rates
The response rates during follow-up were higher 
than 85% for most measures, including sexual 
function, and did not decline over time (Table 
S1B in the Supplementary Appendix). A total of 
55 men (3.3%) stopped completing question-
naires, and some men did not complete all the 
questionnaires at every time point. Outcomes in 
the four domains are presented in this section, 
and selected scores and items are shown in Fig. 1, 
Fig. 2, Fig. 3, and Fig. 4 (details of all patient-
reported outcomes are provided in Table S2 in 
the Supplementary Appendix).
Domain A: Urinary Function and Effect  
on Quality of Life
Prostatectomy had the greatest negative effect on 
urinary continence at 6 months, and although 
there was some recovery, urinary incontinence 
remained worse in the prostatectomy group than 
in the radiotherapy group and active-monitoring 
group at all time points (P<0.001 for each mea-
sure) (Fig. 1A and 1B, and Table S2A in the 
Supplementary Appendix). Radiotherapy and ac-
tive monitoring had little effect on urinary con-
tinence; the rates of urinary incontinence were 
similar in the two treatment groups, although 
the rate rose slightly in the active-monitoring 
group over time. The rate of use of absorbent 
pads increased from 1% at baseline to 46% at 
6 months in the prostatectomy group, as com-
pared with 4% at 6 months in the active-moni-
toring group and 5% at 6 months in the radio-
therapy group. By year 6, 17% of men in the 
prostatectomy group were using pads, as com-
pared with 8% in the active-monitoring group 
and 4% in the radiotherapy group (Fig. 1B). The 
effect of urinary incontinence on quality of life 
was worse in the prostatectomy group for 2 years, 
but then became somewhat similar to that re-
ported in the other groups (Fig. 1C). A similar 
pattern was shown for scores that combined 
lower urinary tract symptoms and incontinence 
(Fig. 1D and 1F). Scores for voiding symptoms 
were a little worse in the radiotherapy group 
than in the other treatment groups at 6 months 
but then returned close to baseline levels and 
Figure 1 (facing page). Outcomes for Urinary Function 
and Effect on Quality of Life.
Shown are the effects of the treatments on urinary 
function (including urinary incontinence) and quality 
of life. The International Consultation on Incontinence 
Questionnaire (ICIQ) incontinence scores, shown in 
Panel A, range from 0 to 21. Panel B shows the percent-
age of men who used one or more absorbent pads per 
day for urinary incontinence, as assessed by the Expand-
ed Prostate Cancer Index Composite (EPIC) instrument. 
In Panel C, the percentages shown are for men who re-
ported a moderate-to-severe incontinence problem, as 
assessed by the ICIQ. The EPIC urinary scores, shown in 
Panel D, comprise several urinary symptoms, including 
incontinence; scores are formed by linear transforma-
tion of raw scores and range from 0 to 100. The Interna-
tional Continence Society Male Short-Form (ICSmaleSF) 
voiding scores, shown in Panel E, range from 0 to 20. 
Panel F shows the percentage of men reporting that 
urinary symptoms affected their quality of life some-
what to a lot, and Panel G, the percentage of men re-
porting nocturia at least two times per night — both 
as assessed by the ICSmaleSF. The P values show the 
strength of evidence for a difference in mean response 
over 6 years of follow-up across the three groups, with 
P values of 0.01 or lower indicating strong evidence of 
a difference. I bars represent 95% confidence intervals.
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Figure 2. Outcomes for Sexual Function and Effect on Quality of Life.
Shown are the effects of the treatments on sexual function (including erectile dysfunction) and quality of life.  
Panel A shows the percentage of men reporting erections firm enough for intercourse. In Panel B, the percentag-
es are for men who reported a moderate-to-severe problem with erectile dysfunction. The EPIC sexual function 
scores, shown in Panel C, range from 0 to 100. The EPIC sexual bother scores, shown in Panel D, range from 0 to 
100. In Panel E, the percentages are for men who reported a moderate-to-severe effect on sexual quality of life. The 
P values show the strength of evidence for a difference in mean response over 6 years of follow-up across the three 
groups, with P values of 0.01 or lower indicating strong evidence of a difference. I bars represent 95% confidence 
intervals.
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Figure 3. Outcomes for Bowel Function and Effect on Quality of Life.
Shown are the effects of the treatments on bowel function and quality of life. In Panel A, the EPIC bowel function 
scores range from 0 to 100. In Panel B, the EPIC bowel bother scores range from 0 to 100. In Panel C, the percent-
ages are for men who reported having loose stools half the time or more. In Panel D, the percentages are for men 
who reported having fecal incontinence at least once per week. In Panel E, the percentages are for men who reported 
having bloody stools half the time or more. In Panel F, the percentages are for men who reported a moderate-to-severe 
negative effect on bowel habits. The P values show the strength of evidence for a difference in mean response over 
6 years of follow-up across the three groups, with P values of 0.01 or lower indicating strong evidence of a difference. 
I bars represent 95% confidence intervals.
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were similar to the scores in the prostatectomy 
group and the active-monitoring group (Fig. 1E). 
Urinary frequency remained similar across the 
treatment groups (Table S2A in the Supplemen-
tary Appendix). The percentage of men reporting 
nocturia increased in all treatment groups; the 
increase occurred particularly in the radiothera-
py group at 6 months, but this percentage then 
decreased to become similar to that in the ac-
tive-monitoring group. The percentage of men 
reporting nocturia returned closest to the base-
line level in the prostatectomy group (Fig. 1G).
Domain B: Sexual Function and Effect  
on Quality of Life
Erectile function was reduced from baseline to 
6 months in all the men, with clear differences 
among the treatment groups (P<0.001) (Fig. 2A). 
At baseline, 67% of men reported erections firm 
enough for intercourse, but by 6 months this 
rate fell to 52% in the active-monitoring group, 
to 22% in the radiotherapy group, and to 12% in 
the prostatectomy group. Erectile function re-
mained worse in the prostatectomy group at all 
time points, and although there was some recov-
ery to 21% with erections firm enough for inter-
course at 36 months, this rate had declined 
again to 17% at 6 years. In the radiotherapy 
group, the percentage of men reporting erections 
firm enough for intercourse increased between 
6 months and 12 months and then declined again 
to 27% at 6 years, and in the active-monitoring 
group, the percentage declined year to year, with 
41% of men reporting this outcome at year 3 and 
Figure 4. Outcomes for Health-Related Quality of Life.
Shown are the effects of the treatments on health-related quality of life. Medical Outcomes Study 12-Item Short-Form 
General Health Survey (SF-12) physical health scores (Panel A) and mental health scores (Panel B) range from 0 to 
100. “Possible case” indicates the percentages of patients, who were assessed with the use of the Hospital Anxiety 
and Depression Scale (HADS), with scores suggesting clinically significant cases of anxiety (Panel C) and depression 
(Panel D). The P values show the strength of evidence for a difference in mean response over 6 years of follow-up 
across the three groups, with P values of 0.01 or lower indicating strong evidence of a difference. I bars represent 
95% confidence intervals.
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30% at year 6. Very similar patterns across the 
treatment groups and over time were observed 
for the other measures of overall sexual func-
tion, bother (the level of the problem experi-
enced), and effect on quality of life (Fig. 2B 
through 2E, and Table S2B in the Supplementary 
Appendix).
Domain C: Bowel Function and Effect  
on Quality of Life
Bowel function and bother scores and the effect 
of bowel habits on quality of life were un-
changed in the prostatectomy group and active-
monitoring group, but scores for these outcomes 
were worse in the radiotherapy group, particu-
larly at 6 months (Fig. 3A, 3B, and 3F, and Table 
S2C in the Supplementary Appendix). The per-
centage of men reporting fecal incontinence and 
loose stools was similar across the treatment 
groups (Fig. 3C and 3D), but the percentage of 
men reporting bloody stools from year 2 onward 
was higher in the radiotherapy group than in the 
other treatment groups (P<0.001) (Fig. 3E). The 
scores on the “bowel bother” assessment and 
the effect on quality of life were also a little 
worse in the radiotherapy group than in the 
other treatment groups (Table S2C in the Supple-
mentary Appendix).
Domain D: Health-Related Quality of Life
The comparisons of health-related quality of life 
revealed no significant differences among the 
treatment groups in the physical and mental 
health subscores of the SF-12 general health 
measure, in scores on the HADS, or in any of the 
symptom or function scale scores of the EORTC 
QLQ-C30 at year 5 (Fig. 4, and Table S2D in the 
Supplementary Appendix).
Discussion
The ProtecT trial has shown that all three treat-
ment groups had similar, very high rates of 
survival after treatment, but higher rates of metas-
tases and disease progression were observed in 
the active-monitoring group than in the two 
radical-treatment groups.1 In this context, under-
standing the effects of the treatments and how 
the treatments affect men’s lives becomes cru-
cial for decision making. The patient-reported 
outcome measures in the ProtecT trial included 
key domains that were recommended by interna-
tional groups,4,27,28 and we followed reporting 
guidelines14 to provide unbiased comparisons of 
the effects of standardized prostatectomy, radio-
therapy, and active-monitoring management 
strategies for PSA-detected clinically localized 
prostate cancer. The findings of the ProtecT 
trial have clarified the distinct effects of pros-
tate-cancer treatments on urinary, sexual, and 
bowel function and condition-specific quality of 
life. The negative effect of prostatectomy on 
urinary continence and sexual function, particu-
larly erectile function, was greatest at 6 months, 
and although there was some recovery, the effect 
was worse than in the other treatment groups 
over 6 years; however, prostatectomy was as-
sociated with no change in bowel function. At 
6 months, the negative effect of radiotherapy 
with neoadjuvant androgen deprivation therapy 
on sexual function, particularly erectile func-
tion, was only a little less than that of prostatec-
tomy, and bowel function, urinary voiding, and 
nocturia were worse in the radiotherapy group 
than in the other groups. However, there was 
then considerable recovery in the radiotherapy 
group for these measures, apart from more fre-
quent bloody stools. In the active-monitoring 
group, sexual (including erectile) function and 
urinary continence and function were affected 
much less than in the radical-treatment groups 
initially but worsened gradually over time, as in-
creasing numbers of men received radical treat-
ments and age-related changes occurred (Table 
S3B in the Supplementary Appendix); bowel 
function was unchanged.
With respect to numbers needed to treat, we 
estimated that treating 4 men with prostatectomy 
or 8 men with radiotherapy rather than active 
monitoring would cause one additional case of 
erectile dysfunction at 2 years; treating 5 men 
with prostatectomy or 143 men with radiother-
apy rather than active monitoring would cause 
one additional case of urinary incontinence at 
2 years. By the end of follow-up at 6 years, urinary 
and sexual function had stabilized in the radio-
therapy group after improving for 2 or 3 years, 
and with the steady decline that was evident in 
the active-monitoring group, the outcomes be-
came similar in the active-monitoring group and 
the radiotherapy group but remained worse in the 
prostatectomy group. These profiles of the ef-
fects of treatments on function were mirrored in 
outcomes reported for the sexual, urinary, and 
bowel quality-of-life items, with some evidence 
of accommodation to changes over time. No ef-
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Variable Treatment
Watchful 
Waiting
Active 
Monitoring 
or Active 
Surveillance
Radical 
Prostatectomy
Radical 
Radiotherapy
percentage of participants
Erection not firm enough for intercourse
At 12-mo follow-up
ProtecT — 51 85 62
SPCG-49 45 — 80 —
Sanda et al.6 — — 75 64
At 24-mo follow-up
ProtecT — 53 81 66
PIVOT11 44 — 81 —
Resnick et al.29 — — 79 61
At 36-mo follow-up
ProtecT — 59 79 66
Smith et al.7 — 54 68 and 87† 68
At 60-mo follow-up: Resnick et al.29 — — 76 72
At 72-mo follow-up: ProtecT — 70 83 73
At 144-mo follow-up: SPCG-430 80 — 84 —
Incontinence: any use of absorbent pads
At 12-mo follow-up
ProtecT — 4 26 4
SPCG-49 16 — 71 —
Sanda et al.6 — — 24 3
At 24-mo follow-up
ProtecT — 4 21 4
PIVOT11‡ 6 — 17 —
Resnick et al.29 — — 27 2
At 36-mo follow-up
ProtecT — 5 20 3
Smith et al.7 — 3 9 and 15§ 3
At 60-mo follow-up: Resnick et al.29 — — 28 4
At 72-mo follow-up: ProtecT — 8 17 4
At 144-mo follow-up: SPCG-430 25 — 54 —
*  Dashes indicate not applicable. The median age of the participants in the Prostate Testing for Cancer and Treatment 
(ProtecT) trial (current study) was 62 years. The mean age of the participants in Scandinavian Prostate Cancer Group 
Study Number 4 (SPCG-4)9 was 64 years. In the study by Sanda et al.,6 the median age of the participants who received 
radical prostatectomy was 59 years, and of those who received radiotherapy, 69 years. The mean age of the participants 
in Prostate Cancer Intervention versus Observation Trial (PIVOT)11 was 67 years. In the study by Resnick et al.,29 the 
median age of the participants who received radical prostatectomy was 64 years, and of those who received radiothera-
py, 69 years. In the study by Smith et al.,7 the mean age of the participants who received active surveillance was 66 
years; of those who received radical prostatectomy, 60 years; and of those who received radiotherapy, 64 years.
†  Erection not firm enough for intercourse at 36 months was reported by 68% of the patients who received nerve-sparing 
prostatectomy and by 87% of the patients who received non–nerve-sparing prostatectomy.
‡  Patient reports of “have a lot of problems with urinary dribbling,” “lose larger amounts of urine than dribbling but not 
all day,” “have no control over urine,” or “have an indwelling catheter” were used to define incontinence instead of 
“any use of pads.”
§  Any use of pads was reported by 9% of the patients who received nerve-sparing prostatectomy and by 15% of the pa-
tients who received non–nerve-sparing prostatectomy.
Table 2. Comparisons of Key ProtecT Trial Outcomes with Those Found in Other Trials and Cohorts.*
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fects were observed with respect to general health 
status (mental or physical) or anxiety or depres-
sion in any treatment group at any time or in 
cancer-related quality of life at 5 years.
The paucity of published data, lack of consis-
tency in definitions of outcomes, and variability 
in timing of assessment severely constrain our 
ability to compare ProtecT findings directly with 
those of other randomized trials or major cohort 
studies of treatments.3,5 Table 2 presents the 
findings for two specific items that we could 
compare — erectile function and the use of pads 
for urinary incontinence. The findings in the 
ProtecT trial were similar to those in the SPCG-4 
trial and PIVOT with respect to erectile function 
after prostatectomy and active monitoring (or 
watchful waiting).9,11,30 The slightly worse results 
in observational cohorts6,7,29 could be related to 
age or selection biases. The percentage of pa-
tients who required the use of pads after prosta-
tectomy or active monitoring was considerably 
lower in the ProtecT trial than in the SPCG-4 
trial and was similar to that in PIVOT; the re-
sults regarding pad use after radiotherapy were 
similar in the three observational studies at all 
time points (Table 2). Broadly similar results 
were also found with respect to bowel function 
and urinary symptoms after radiotherapy4,6 and 
for urinary voiding after prostatectomy.6 The 
EPIC scores in the ProtecT trial were similar to 
those in other studies.31,32 Other studies also re-
ported similar results for assessments of general 
health-related or psychological aspects of quality 
of life.3,9,33
The primary analysis of patient-reported out-
come measures according to treatment group is 
essential for policy development, but the inter-
pretation of the overall scores for decision mak-
ing by an individual patient or clinician is diffi-
cult because factors related to the design and 
analysis of the ProtecT trial and its treatment 
policies will have affected some scores. The re-
ceipt of therapies to ameliorate the side effects 
of treatments will also have affected some scores. 
These issues are considered further in section S3 
in the Supplementary Appendix. Determining the 
clinical significance of outcome measures is also 
challenging; minimal clinically important differ-
ences were proposed to be half the baseline 
standard deviation or 10 points on some scores 
but were not defined for other scores.15 We have 
provided figures for key outcomes according to 
treatment group (Fig. 1, Fig. 2, Fig. 3, and Fig. 4), 
as well as a table containing all summary statis-
tics, with P values that were not adjusted for 
multiple testing (Table S2 in the Supplementary 
Appendix), to enable readers to make their own 
judgments.
The interventions in the ProtecT trial remain 
the three most common contemporary methods 
of treatment, but there have been developments 
since the study began. In the ProtecT trial, 
among the men in the prostatectomy group, 324 
received open retropubic procedures, 23 received 
laparoscopic procedures, and 25 received robot-
assisted procedures (the specific procedure was 
not specified in the case of 19), and most of the 
prostatectomies were nerve sparing (205 bilateral, 
53 unilateral, and 12 unspecified). Observational 
studies suggest that minimally invasive proce-
dures result in a shorter length of hospital stay 
and fewer adverse events than do open proce-
dures.34 However, a recent trial has shown that 
the functional outcomes 12 weeks after a robot-
assisted procedure were similar to those after an 
open retropubic approach,35 and another study 
showed levels of erectile dysfunction (88%) and 
urinary incontinence (31%) among men receiv-
ing robot-assisted procedures that were very simi-
lar to those in the prostatectomy group in the 
ProtecT trial at 12 months36 The radiotherapy 
protocol in the ProtecT trial conforms with con-
temporary guidelines,37 but other techniques 
such as brachytherapy and intensity modulation 
have been introduced. Although many active-
surveillance programs were developed during the 
ProtecT trial period, there remains little consen-
sus on inclusion criteria or monitoring and inter-
vention strategies.38 The active-monitoring policy 
in the ProtecT trial had less selective inclusion 
criteria than do many active-surveillance pro-
grams, and follow-up did not include scheduled 
repeat biopsies or magnetic resonance imaging; 
however, the rate of men in the active-monitoring 
group in the ProtecT trial who changed treatment 
strategies was similar to that in other studies.
There are strengths and limitations in the de-
sign and conduct of the ProtecT trial. Key strengths 
are the inclusion of radiotherapy, the use of 
validated patient-reported outcome measures, 
well-balanced baseline data, high response rates, 
and concordance between measures across the 
range of domains affected by treatments for local-
ized prostate cancer. A high rate of eligible par-
ticipants underwent randomization (62%).39,40 The 
generalizability of the ProtecT trial is enhanced 
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by its inclusion in a larger trial evaluating pros-
tate cancer screening. In the Cluster Random-
ized Trial of PSA Testing for Prostate Cancer 
(CAP), general practices were randomly assigned 
to form the intervention group or the control 
group (the intervention group enrolled partici-
pants in the ProtecT trial and the control group 
followed usual care, which did not include an 
organized program of PSA testing).41 The diag-
nosis of prostate cancer in the ProtecT trial 
participants was made after population-based 
PSA testing and standardized diagnostic proce-
dures.12 An important limitation in the current 
trial was that only a small number of men of 
nonwhite race were included, although this re-
flected the population in the recruitment areas.15 
Other limitations are related to changes in diag-
nostic and treatment strategies since the incep-
tion of the trial and the low levels of previous 
PSA testing in the population42; however, as con-
firmed on biopsy, the ProtecT trial involved 
numbers of men who had stage T1 disease (76%) 
and disease with a Gleason score of 6 (on a scale 
of 2 to 10, with higher scores indicating a worse 
prognosis) (77%) that were similar to or higher 
than the numbers in other treatment or screen-
ing trials in the era of PSA testing.11,43,44
This primary analysis has provided data on 
patient-reported outcomes over 6 years after 
treatment assignment in the ProtecT trial. These 
data, combined with the findings of the com-
panion article,1 can be used by policymakers 
who are developing guidelines and by patients 
and clinicians who are making decisions about 
treatments for newly diagnosed localized pros-
tate cancer or who are contemplating PSA test-
ing. However, follow-up for an additional 5 to 10 
years is required to fully inform decisions in-
volving the tradeoff between the shorter-term 
effects of the management strategies shown here 
and the longer course of progression and treat-
ment of prostate cancer in the context of the 
onset of other life-threatening conditions.
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